Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Diabetes Care 29:1545-1553, 2006
DOI: 10.2337/dc05-2462
© 2006 by the American Diabetes Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hodis, H. N.
Right arrow Articles by Buchanan, T. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hodis, H. N.
Right arrow Articles by Buchanan, T. A.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Pathophysiology/Complications
Original Article

Effect of Peroxisome Proliferator–Activated Receptor {gamma} Agonist Treatment on Subclinical Atherosclerosis in Patients With Insulin-Requiring Type 2 Diabetes

Howard N. Hodis, MD1,2,3, Wendy J. Mack, PHD2,3, Ling Zheng, PHD2,4, Yanjie Li, MD3, Mina Torres, MS2,3, Diego Sevilla, PA1, Yolanda Stewart, BS1,4, Barbara Hollen, MPH1, Karla Garcia, BA1,4, Petar Alaupovic, PHD5 and Thomas A. Buchanan, MD1,4

1 Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, California
2 Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, California
3 Atherosclerosis Research Unit, University of Southern California Keck School of Medicine, Los Angeles, California
4 General Clinical Research Center, University of Southern California Keck School of Medicine, Los Angeles, California
5 Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma

Address correspondence and reprint requests to Howard N. Hodis, MD, Atherosclerosis Research Unit, University of Southern California Keck School of Medicine, 2250 Alcazar St., CSC 132, Los Angeles, CA 90033. E-mail: athero{at}usc.edu

OBJECTIVE—To determine the effect of thiazolidinedione treatment on subclinical atherosclerosis progression in insulin-requiring patients with clinical characteristics suggesting type 2 diabetes.

RESEARCH DESIGN AND METHODS—Eligible participants (n = 299) were randomized within strata of baseline common carotid artery (CCA) intima-media thickness (IMT) (<0.8 mm, ≥0.8 mm) to 400 mg troglitazone daily or placebo for 2 years. A general linear mixed-effects model was used to compare the rate of change in CCA-IMT between treatment groups.

RESULTS—Overall, average rates of CCA-IMT change were not significantly different between troglitazone- and placebo-treated subjects (0.0030 ± 0.021 vs. 0.0066 ± 0.021 mm/year; P = 0.17). In the stratum of subjects with CCA-IMT ≥0.8 mm, troglitazone significantly reduced the progression of CCA-IMT relative to placebo (0.0013 ± 0.022 vs. 0.0084 ± 0.023 mm/year; P = 0.03). Fasting glucose, insulin, and HbA1c were significantly lower in troglitazone- versus placebo-treated subjects (P < 0.01). Whereas blood pressure significantly differed between treatment groups in the ≥0.8-mm stratum, there was no difference between treatment groups in the <0.8-mm stratum.

CONCLUSIONS—Insulin sensitization and reduction in blood pressure may be contributory mechanisms by which troglitazone reduced subclinical atherosclerosis progression in this cohort of well-controlled insulin-dependent patients with clinical characteristics suggesting type 2 diabetes.

Abbreviations: ALT, alanine aminotransferase • CCA, common carotid artery • IMT, intima-media thickness • PPAR, peroxisome proliferator–activated receptor • TZD, thiazolidinedione


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 CirculationHome page
M. Davidson, P. M. Meyer, S. Haffner, S. Feinstein, R. D'Agostino Sr, G. T. Kondos, A. Perez, Z. Chen, and T. Mazzone
Increased High-Density Lipoprotein Cholesterol Predicts the Pioglitazone-Mediated Reduction of Carotid Intima-Media Thickness Progression in Patients With Type 2 Diabetes Mellitus
Circulation, April 22, 2008; 117(16): 2123 - 2130.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
C.-P. Liang, S. Han, T. Senokuchi, and A. R. Tall
The Macrophage at the Crossroads of Insulin Resistance and Atherosclerosis
Circ. Res., June 8, 2007; 100(11): 1546 - 1555.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
J. Lindenfeld and F. A. Masoudi
Fluid Retention With Thiazolidinediones: Does the Mechanism Influence the Outcome?
J. Am. Coll. Cardiol., April 24, 2007; 49(16): 1705 - 1707.
[Full Text] [PDF]

Home page
 JAMAHome page
T. Mazzone, P. M. Meyer, S. B. Feinstein, M. H. Davidson, G. T. Kondos, R. B. D'Agostino Sr, A. Perez, J.-C. Provost, and S. M. Haffner
Effect of Pioglitazone Compared With Glimepiride on Carotid Intima-Media Thickness in Type 2 Diabetes: A Randomized Trial
JAMA, December 6, 2006; 296(21): 2572 - 2581.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2006 by the American Diabetes Association.